Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems

Research output: Contribution to journalReview articlepeer-review

34 Citations (Scopus)

Abstract

Antiplatelet therapy has been established as a preventive medicine for ischemic cardiovascular diseases both at acute and chronic phases. This therapy is also crucial for the prevention of thrombotic events after coronary stent implantation. So far, many lines of clinical evidence have demonstrated the beneficial effects of aspirin (an irreversible cyclooxygenase inhibitor) and thienopyridine derivatives (adenosine diphosphate (ADP)-receptor P2Y12 inhibitors). Recently, it has been reported that the cardiovascular risk is elevated in patients with platelets resistant to these drugs, compared to the good responders. One of the current problems to be solved in antiplatelet therapy is to find out patients resistant to the antiplatelet therapy and improve its preventive effects. In addition to aspirin and thienopyridines, several types of drugs with antiplatelet effects are currently available in clinical practice. Clinical evidence has recently been accumulating for these drugs that can be potential alternatives in patients with aspirin or thienopyridine resistance. In this review, the mechanisms, evidence and approach to the present problems of drugs with antiplatelet effects are discussed.

Original languageEnglish
Pages (from-to)162-172
Number of pages11
JournalAnnals of Medicine
Volume38
Issue number3
DOIs
Publication statusPublished - 2006 May 1
Externally publishedYes

Keywords

  • Antiplatelet drugs
  • Aspirin
  • Aspirin resistance
  • Clopidogrel
  • Clopidogrel resistance
  • Platelet activation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems'. Together they form a unique fingerprint.

Cite this